Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Inovio Pharmaceuticals (INO) PT Raised to $14 at Aegis Capital
May 25, 2017 8:15 AM EDTAegis Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining a Buy rating after the company announced preliminary data on its PENNVAX-GP HIV vaccine which showed an immune response in nearly all patients.
Analyst Difei Yang commented, "The 94... More
